fibrinogen complex

Overview

The fibrinogen complex refers to the circulating plasma glycoprotein system centered on fibrinogen, a key component of hemostasis and thrombosis. In normal physiology, fibrinogen is converted by thrombin into fibrin, which polymerizes to form the structural basis of a blood clot. Because of this central role, fibrinogen is closely linked to coagulation, platelet aggregation, wound repair, and inflammatory responses.

Clinically, fibrinogen is widely used as a biomarker of coagulation status and systemic inflammation. Elevated fibrinogen is commonly associated with chronic inflammatory states and prothrombotic risk, while reduced levels may reflect consumption or impaired synthesis in severe illness or bleeding disorders. In recent biomedical research, fibrinogen has been examined in contexts ranging from acute ischemic stroke and severe trauma to COVID-19, Crohn's disease, polycystic ovary syndrome, and device hemocompatibility testing.

Focus of Latest Publications

Recent research on fibrinogen complex spans diagnostic applications, therapeutic targeting, and tissue engineering innovations. Fibrinogen levels have emerged as a valuable clinical biomarker across multiple disease contexts. In pediatric nephrotic syndrome, elevated serum fibrinogen correlated independently with respiratory tract infection risk, with combined measurement of fibrinogen and urinary α1-microglobulin demonstrating superior predictive accuracy (AUC >0.917) for early risk stratification. Similarly, in severe trauma patients, fibrinogen trajectory alongside platelet and D-dimer levels provided prognostic information for venous thromboembolism prediction. Fibrinogen has also been identified as a circulating protein marker in smoking-induced chronic obstructive pulmonary disease, predicting disease severity and exacerbation risk.

The association between systemic fibrinogen elevation and pathological coagulation has been documented across multiple acute and chronic conditions. In severe COVID-19, elevated fibrinogen levels showed statistically significant associations with coagulopathy parameters, correlating with the disease's inflammatory-coagulation crosstalk. Abdominal adiposity—particularly visceral fat accumulation—was associated with increased plasma fibrinogen and related prothrombotic coagulation markers, suggesting a metabolic link to thrombotic disease risk. In polycystic ovary syndrome, fibrinogen emerged as a differentially expressed protein with diagnostic potential, validated through ELISA-based proteomic approaches.

Therapeutic strategies targeting fibrinogen are advancing on two fronts. Anticoagulant research is exploring fibrinogen and fibrin as novel intervention targets to reduce thrombotic disease burden while potentially improving the safety profile of current anticoagulants beyond direct oral anticoagulants. Concurrently, fibrinogen derivatives are being engineered for tissue regeneration; methacrylated fibrinogen (FibMA) was incorporated into interpenetrating polymer network hydrogels with photochemically reinforced fibrillar architectures, achieving precise control over mechanical properties and supporting robust three-dimensional cell growth with reduced compaction, demonstrating dual potential as both a therapeutic target and a biomaterial scaffold. In acute ischemic stroke, baseline fibrinogen levels were evaluated for their impact on the differential efficacy and safety profiles of distinct thrombolytic agents, reflecting the complex role of fibrinogen in both pathophysiology and treatment response.